Physician profile
Jonathan Paul Schmidt
NPI 1467018457
$2,098.33
in general payments reported to CMS, 2019-2025
13 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $652 · 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,063.27 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $602.30 | 2024-2025 | Interstim, Altaviva |
| Janssen Biotech, INC. | $387.51 | 2024-2025 | Erleada |
| Sumitomo Pharma America, INC. | $227.30 | 2024-2025 | Gemtesa, Orgovyx |
| Baxter Healthcare | $145.86 | 2025 | Floseal |
| Stryker Corporation | $143.54 | 2024 | 1788 |
| Accord Healthcare, INC. | $128.24 | 2025 | |
| Sanara Medtech INC. | $127.27 | 2025 | Celleraterx |
| Endo USA, INC. | $108.78 | 2024-2025 | Xiaflex, Aveed |
| Procept Biorobotics Corporation | $101.53 | 2024-2025 | Aquabeam System |
| Astrazeneca Pharmaceuticals LP | $54.66 | 2025 | Imfinzi, Lynparza |
| Abbvie INC. | $30.36 | 2024-2025 | |
| Urogen Pharma, INC. | $22.32 | 2025 | |
| Merck Sharp & Dohme LLC | $18.66 | 2025 | Keytruda, Welireg, Keytruda Qlex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.